RxDoctor Payments Data

Yaneidy Candelario, APRN

Nurse Practitioner · Lehigh Acres, FLNPI 1790467280

Payments from drug & device makers

$982in general payments, 2019–2025

Across 25 payments — averaging $39.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$211
  • AstraZeneca$188
  • GSK$139
  • Boehringer Ingelheim$136
  • Bayer$125
  • Lilly USA, LLC$42
  • plus $141 from 6 others

What the payments were for

  • Food & beverage$982100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$982 in reported general payments places this provider in the 70th percentile of 8,290 nurse practitioner providers in Florida.

See all nurse practitioner providers in Florida

Medicare billing

Part B allowed, 2024
$9,431
Medicare patients
42
Services billed
143

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin25$36,838
MounjaroTirzepatide21$23,894
SymbicortBudesonide/Formoterol Fumarate13$3,071
Lubiprostone18$1,314
Albuterol Sulfate HfaAlbuterol Sulfate46$1,049
Gabapentin55$940
Ventolin HfaAlbuterol Sulfate14$762
Diclofenac Sodium18$623
Methylprednisolone32$563
Nabumetone52$545
Glipizide13$540
ValacyclovirValacyclovir Hcl13$519
Methocarbamol26$486
Hydroxyzine Hcl23$479
Esomeprazole Magnesium12$473

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$136$36,83825 claims
Lilly USA, LLCMounjaro$42$23,89421 claims
AstraZenecaSymbicort$188$3,07113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 8,290 nurse practitioner providers in Florida.

Other nurse practitioner in Lehigh Acres

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →